Recent data suggests both models produce comparable clinical outcomes when patients remain adherent to treatment
[1] [2] This effect has contributed to its notable impact on weight loss, though in the UK it is primarily licensed for diabetes management rather than obesity treatment alone (though a higher-dose formulation, Wegovy, is available specifically for weight management)
Expression and role of phosphatidylcholine-specific phospholipase C in human NK and T lymphocyte subsets
Rapid or extreme weight loss can accelerate lean mass and bone density decline , potentially increasing frailty and fracture risk
doi: 10.1056/NEJMoa2206038 119 AdriaenssensAEBiggsEKDarwishTTadrossJSukthankarTGirishMet al
While treatment with the GLP-1 receptor agonist did not impact the average drinks per calendar day or the number of drinking days, it significantly lowered the number of drinks per drinking day as well as weekly alcohol cravings